NASDAQ
Sagimet Biosciences Inc. - Series A (SGMT)
♥ 315 Thanks from members
Net web sentiment for Sagimet Biosciences Inc. (SGMT) is positive, driven by strong clinical momentum for its lead drug denifanstat in acne, a recent $175M equity raise extending its cash runway through 2028, and high retail and analyst interest despite ongoing cash burn.